PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Disease overview • Conjunctivitis • Viral conjunctivitis • Signs and symptoms • Diagnosis • Management • Epidemiology • Economic burden PART 06: Pipeline analysis • FST-100 • APD-209 eye drops • SPL7013 • EKC-Cide • PP-001 PART 07: Market landscape • Market overview • Market size and forecast • Viral conjunctivitis drugs market in US • Five forces analysis PART 08: Market segmentation by route of administration • Topical • Oral • Intravitreal PART 09: Geographical segmentation • Global viral conjunctivitis drugs market by geography 2015-2020 • Viral conjunctivitis drugs market in Americas • Viral conjunctivitis drugs market in EMEA • Viral conjunctivitis drugs market in APAC PART 10: Market drivers • Rising awareness • Unmet needs for viral conjunctivitis • High prevalence PART 11: Impact of drivers PART 12: Market challenges • Low diagnosis rate • Adverse effects and limited efficacy of drugs • Satisfaction with existing therapies • Availability of alternative therapies PART 13: Impact of drivers and challenges PART 14: Market trends • Strategic alliances and M&A • Use of off-label drugs • Rise in R&D PART 15: Vendor landscape • Akorn • Alcon • Allergan • Bausch & Lomb • Other prominent vendors PART 16: Appendix • List of abbreviations PART 17: Explore Technavio   Exhibit 01: Product offerings Exhibit 02: Types of conjunctivitis Exhibit 03: Major types of viral conjunctivitis Exhibit 04: Signs and symptoms of types of viral conjunctivitis Exhibit 05: Diagnostic algorithm for viral conjunctivitis Exhibit 06: Drugs used to treat conjunctivitis Exhibit 07: Comparison of prevalent rates in different types of conjunctivitis among adults and pediatric population (%) Exhibit 08: Global viral conjunctivitis drugs market: Pipeline portfolio Exhibit 09: Global viral conjunctivitis drugs market 2015-2020 ($ millions) Exhibit 10: Snapshot of global viral conjunctivitis drugs market Exhibit 11: Percentage share of US in the global viral conjunctivitis drugs market 2015 Exhibit 12: Viral conjunctivitis drugs market in US 2015-2020 ($ millions) Exhibit 13: Five forces analysis Exhibit 14: Global viral conjunctivitis drugs market segment by route of administration Exhibit 15: Global viral conjunctivitis drugs market by geography 2015 Exhibit 16: Viral conjunctivitis drugs market by geography 2015-2020 ($ millions) Exhibit 17: Viral conjunctivitis drugs market in Americas 2015-2020 ($ millions) Exhibit 18: Viral conjunctivitis drugs market in EMEA 2015-2020 ($ millions) Exhibit 19: Viral conjunctivitis drugs market in APAC 2015-2020 ($ millions) Exhibit 20: Global viral conjunctivitis drugs market: YoY growth and revenue based on geography 2015-2020 Exhibit 21: Impact of drivers Exhibit 22: Impact of drivers and challenges Exhibit 23: Akorn: YOY growth and revenue generated from ophthalmic segment 2011-2013 ($ millions) Exhibit 24: Akorn: Key takeaways Exhibit 25: Alcon: Business segmentation by revenue 2014 Exhibit 26: Alcon: YoY growth and revenue generated from sales of ophthalmic products 2011-2014 ($ billions) Exhibit 27: Alcon: Key takeaways Exhibit 28: Allergan: Key takeaways Exhibit 29: Bausch & Lomb: Key takeaways

Akorn, Alcon, Allergan, Bausch & Lomb, Adenovir Pharma, Marinomed Biotechnologie, Mediolanum Laboratoires, NanoViricides, Nicox, Novartis, Panoptes Pharma, Rapid Pathogen Screening, Shire, Starpharma, Valeant Pharmaceuticals.